Established in 1958 and headquartered in the City of Jinan, Qilu Pharmaceuticals is one of the leading pharmaceutical companies in China with a comprehensive industrial value chain focusing on development, manufacture and marketing of drug substances, drug products and biologics. After years of development and expanding, the company now has 9 manufacturer sites, 13 domestic subsidiaries, 10 overseas subsidiaries and over 9,000 staff worldwide. With a sales revenue of approximately $2.1 billion, Qilu Pharmaceuticals products are available in over 70 countries globally.
 

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers’ most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 13,500 people worldwide. Information about Agilent is available at www.agilent.com.
 

BIOCHECK Inc. is a comprehensive provider of services for new antibody discovery and immunoassay development. With our proprietary single B cell cloning technology, we can directly enrich positive B cells, isolate IgG genes and express recombinant antibodies for downstream immunoassay development. Our highly experienced assay development team can help customers identify recombinant antibodies for various applications, including IHC, flow cytometry, ELISA and the Ultra-sensitive SimoaTM assay.
 

 

 

Founded in August 2011, Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out in China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as Fidelity, Lilly Asia Ventures, Legend Capital, SDIC Fund Management, China Life, Temasek, Hillhouse, Ping An, Taikang Insurance Group, and others.  In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while outside of China Lilly develops and commercializes multiple immuno-oncology biologics within the alliance.  The transaction not only brought the largest upfront payment from a global company to a Chinese company, but also was the first time a biologic was out-licensed to a global company for global development.
 

 

 

 

Novoprotein Scientific is a company within the ever-growing field of biotechnology and bio-research. Focusing on the production of research grade recombinant proteins, Novoprotein Scientific has completed more than 4,000 custom projects with a success rate of 85% in our twelve years of business. Every year is bigger than the last, and Novoprotein continues to grow and increase Novoprotein’s expertise in our four well-established expression systems for unique and customized projects. Novoprotein skillfully uses mammalian, E.coli, yeast, and baculovirus expression systems and have a system capacity that has since reached gram sized project scales. Novoprotein Scientific also has an impressive catalog list of over 2,000 established products of various uses and designations with guaranteed activity. Product categories include Cytokines, Chemokines, Growth Factors, Immune Checkpoints, Hormones, Enzymes, and more. Novoprotein also has offices on American shores, which not only acts as a direct contact for customer purchasing and inquiries, but also acts as an effective scientific liaison between the labs and consumer to best assist with technical questions, and to closely work with customers with their custom projects.
 

 

 

 

Zhejiang Teruisi Pharmaceutical Inc. is an innovative biopharmaceutical company with CDMO service. The company is on the promise of delivering quality and affordable Biopharmaceuticals worldwide. Led by Dr. Youling Wu, a distinguished expert from National Thousand Talents Program, Teruisi has built a team of top biopharmaceutical experts. Teruisi strive to improve patients’ life quality by providing quality and affordable protein therapeutics through technical innovation. Teruisi has advanced a product portfolio consisting of 9 antibodies focusing on treatments against variety malignant tumors, such as lymphoma, lung cancer, colorectal cancer, renal cancer, pancreatic cancer, liver cancer and breast cancer, etc. The product pipeline contains mAb, antibody drug conjugate (ADC), immune-oncology, bispecific antibody, nanobody with novel targets (“first-in-class”.) for unmet medical needs. Teruisi has built a large-scale (4 x 5000 L = 20000L) commercial manufacturing facility that met US/FDA, EU/EMA and cFDA’s GMP standards. It is the first of this kind in China and it will the one to break through the large scale manufacture barrier in China.
 

 

 

 

 

ACROBiosystems is a leading manufacturer of recombinant proteins. We provide high quality protein reagents to the pharmaceutical research community. The company employs an application-oriented product development strategy, with a particular focus on protein labeling technology. Our flagship MABSOL® biotinylated protein collection offers a new set of solution to assay development. These pre-labeled products have been successfully adapted to Biacore, AlphaLisa, MSD, among other established platforms. Throughout the years, ACROBiosystems keeps growing, adapting, and evolving to meet the rising expectation from the customers. Our scientists are transforming ideas into reality on a daily basis, while the support team is working around the clock to ensure all customer needs are addressed in a timely manner. We hope we can become the one-stop solution for your protein needs in near future and, in the meantime, contribute our own efforts to the development of healthcare industry.
 

 

Jianshun Biosciences Co., Ltd. is a leader in industrial and research scale cell culture media business. The company is committed to devloping and manufacturing “customized serum-free, chemically defined cell culture media”, and focused on development and research of process and technology. JS Bio’s cell culture media are applied in biopharmaceutical manufacturing (Manufacturing of recombinant therapeutic proteins, including monoclonal antibody), cell therapy, and human/animal vaccines. JS Bio provides world-class cell culture media optimization and process development services. JS Bio independent research and development hundreds of commercial productions and applied to CHO,BHK21, MDCK, MDBK, VERO, 293, SF9, PK15, marc145, ST cell culture, etc. JS Bio also provide complete solutions such as vector design and construction, cell development, cell line evaluation, cell culture process development and amplification, medium preparation, preclinical / clinical protein stock production, and clinical reporting support for customers.
 

JOINN Labs is a leading nonclinical CRO founded in China in 1995. JOINN has been GLP certified by CFDA since 2005, accredited by AAALAC since 2008. JOINN passed the US FDA inspections in 2009, 2013 and 2016, received OECD GLP Certificate in 2015. We provide customized studies tailored to our clients’ needs that encompass the full spectrum of services from drug development to final registration, including drug screening, pharmacological efficacy studies, GLP toxicology assessment, pharmacokinetic/pharmacodynamics studies, DMPK/bioanalysis, ophthalmic specialty and evaluation of the inhaled therapeutics etc.  A myriad of pivotal safety study reports from JOINN have been accepted by CFDA, the authorities of many other countries, and most importantly the US FDA, for supporting IND applications and commencing clinical trials.
  Ab Studio Inc. is a start-up Biotech founded in March 2017 in SF bay area, USA. Founder and leading scientists have extensive expertise in the field of therapeutic antibody development. Ab Studio aims to support the whole therapeutic antibody R&D field with 1) novel technology platforms on making bispecific and internalization antibodies 2) high quality antibody discovery and engineering services 3) CMC and IND-filing partnering. We deeply believe in the “quality by design” concept and wish our work can strongly support your in-house pipeline.
 

 

Genscript is the world’s leading biotech company providing life sciences services and products. With gene synthesis, peptide, protein, antibody and preclinical drug development service capabilities, we are internationally recognized as a leading biotech company specializing in fundamental life sciences research and early-phase drug discovery services. As of 2015, more than 12,000 peer-reviewed journal articles cited GenScript’s services and products, making GenScript the most frequently cited biotech company in the world.
 

 

 

 

Sartorius Stedim Biotech is a leading international provider of integrated solutions for the biopharmaceutical industry. With our extensive portfolio of products, technologies and services, we cover wide areas of the biopharmaceutical process chain, ranging from fermentation, cell cultivation, filtration and purification to media storage and transportation. In process filtration, fermentation and fluid management, our company holds leading positions in the markets it serves across the globe. Our single-use products that have meanwhile become established in nearly all process steps are playing an increasingly important role in the manufacture of biopharmaceuticals. As a result, we help our customers produce biological medications and vaccines safely and efficiently.
 

 

 

MabPlex provides world-class solutions to biopharmaceutical clients globally. Our company is based on the quality by design (QbD) principle, from site construction to manufacturing and delivery of our clients’ biologic drugs. With an expert team adept in both chemistry and biology, MabPlex provides global CDMO services in biopharmaceuticals. Capabilities span the scope from monoclonal antibodies (mAbs) and fusion proteins to the most complicated antibody–drug conjugates (ADCs). Our manufacturing space offers flexibility and complete services from upstream cell line development to manufacturing and fill–finish of commercial drug products. Our technical expertise allows us to provide effective high-quality solutions for your biomanufacturing needs. With that, MabPlex delivers our commitment to you through our quality manufacturing, meeting your expectations.
 

 

 

Rapid Novor Inc is the world’s leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence the antibody proteins without needs to access the cell line. As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company’s REmAbTM antibody protein sequencing service has allowed the accurate sequencing of any given antibody proteins routinely. The company’s WILDTM service is the first commercially available service that can accurately distinguish the isomeric Isoleucine and Leucine using mass spectrometry.
 

 

 

 

 

TOT BIOPHARM Co., Ltd., founded in 2010, is a bio-pharmaceutical company specializing in developing, manufacturing and commercializing oncology drugs. TOT BIOPHARM has 3 technology platforms: (1) monoclonal antibodies/ ADCs, (2) oncolytic virus products, and (3) specialty anti-cancer drugs (liposomal drugs). TOT BIOPHARM establishes a competitive oncology drugs manufacturing base in Suzhou Industrial Park. The stage 1 construction, completed in 2012, includes a 500L-biologic pilot plant, OEL-5 isolator for ADCs, BSL-2 certified viral facility, and small molecule plants (oral and injectable). The Stage 2 construction, expected to complete in 2018, is a state- of-the-art antibody production site with 5 lines of 2,000L-biologic reactors to accommodate the high-quality commercial manufacturing. TOT BIOPHARM has developed its own sales and marketing team and networking, which covers over 400 major hospitals and keeps close cooperation with oncology experts and key opinion leaders in China. TOT BIOPHARM is your best partner in the fight against cancer.
 

 

 

3S Pharmaceutical Group is a leading bio-pharmaceutical company integrating R&D, production and sales, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Group owns more than 80 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Group owns 4 R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 25 kinds of products under R&D, 16 kinds of them are under R&D as the national first-class new drugs. The Group also owns 6 production bases complying with GMP standards. In the future, 3S Pharmaceutical Group will continue to uphold the concept of “Care for Life, Cherish Life, Create Life” to create a world’s leading bio-pharmaceutical company in China.
 

 

Biointron Biological Inc. was founded in 2012 and specialized in antibody CRO service. We provide mouse hybridoma generation, hybridoma sequencing, high throughput recombinant antibody production, antibody humanization & affinity maturation, biacore testing, bulk recombinant antigen and avitag-biotinylated proteins, etc. It only takes us 2 weeks from gene synthesis to recombinant antibody delivery, which stems from our focus. In the past 2017, we served nearly 100 biopharma companies and delivered more than 3,000 recombinant antibodies. Look forward to cooperating with you!Contact us: Website: www.biointron.com,  E-mail: info@biointron.com,  Tel:+86-400 828 8830
 

Hangzhou HuaAn Biotechnology Co., Ltd (HuaBio) was founded in 2007, whose headquarter is located in Hangzhou, China. HuaBio is committed to providing high-quality antibodies and antibody production service for global scientific researchers and industrial customers. Huabio has developed over 3000 antibodies including recombinant rabbit monoclonal antibodies, mouse monoclonal antibodies, rabbit polyclonal antibodies, phosphor-specific antibodies, secondary antibodies. Since 2015, we began to specialize in the large-scale production of recombinant rabbit monoclonal antibodies. HuaBio is also committed to providing the highest quality of custom antibody services in shortest-time. By now, we have accomplished more than 3000 customized antibody projects in various research fields such as Neuroscience, Epigenetics, Stem Cells, Microbiology, Signal Transduction Apoptosis and so on.
 

 

 

 

Simcere Pharmaceutical Group was founded on March 28, 1995 with an enterprise mission to “discover and develop high-quality medicines for patients.” Since its inception, we have grown from a registered capital of 2.78 million to total assets of over 3 billion yuan, from a few dozen people to a R&D-driven pharmaceutical enterprise with more than 3,000 talents, and from an annual tax of less than a million to about 500 million yuan. We have ranked among “the top 100 Chinese Pharmaceutical Companies” for consecutive years, and our growth goes beyond the numbers. We now own over 50 products that cover Oncology, Cardiovascular and Cerebrovascular, Anti-infection, Rheumatology and other therapeutic areas. We have three products (Endostar®, Sinofuan®, Iremod®) that were the first-to-launch in the world, and six products (BICUN®、ZAILIN®、ANTINE®、YEQING®、JIEBAISHU®、Newanti®) that were the first-in-class in China. Since 2007, we have submitted over 200 domestic and PCT patent applications. Over 10 innovative drugs are being studied in clinical trials, which will broaden our current marketed product portfolio. SIMCERE, PIONEER THE HEALTHCARE FRONTIER.
 

 

 

 

Harbour BioMed is a global biotechnology company developing innovative therapeutics  in the field of  immuno-oncology and inflammatory diseases. The company’s discovery and development programs are centered around its two patented transgenic mouse platforms generating fully human monoclonal antibodies. The company is building its proprietary pipeline internally, through collaborations with co-development partners, as well as through select preclinical and clinical stage asset acquisitions. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. Harbour BioMed has operation and an R&D site in Shanghai, China, business operations and innovation center including research laboratory in Boston, USA, and an antibody platform innovation center in Rotterdam, The Netherlands.

 

 

 

 

 

The Chengdu Medical City is located at the Wenjiang District which is the vital part of Chengdu. It is the most important area in development of Chengdu bio-pharmaceutical industry. It is divided into Zones A & B, with an overall planning area of 35.85 km2. It focuses on developing three industries, including medical science, medical treatment, and medicines. It has successfully established three industry bases, such as I-Bridge Capital, Cybernaut and TCL, with raised funds of RMB 1.6 billion. In 2017, 10 billion RMB of investment in Wuxi health industrial park project located in Wenjiang. The Chengdu Medical City “Three-Medical Innovation Center” Project (Phase III) is the Phase I Project set up in scientific innovative base of Chengdu Medical City. Such project was invested and constructed by Chengdu GeUnion Kehai Health Technology Co., Ltd. which is a state-owned enterprise at Wenjiang District. It will have been completed for use by June of 2018. Such project intends to construct the innovation and industrial promotion platforms serving for “three-medical integration”, including five platforms such as technology, information, talents, finance, government affairs and incubation services, and create a high-end bio-pharmaceutical professional ecological park integrating technical research and development, pilot production, industrialization service, living as well as comprehensive set. Consulting hotline: 028—8277 6878.
 

 

Luye Pharma Group is a professional pharmaceutical enterprise built on a solid foundation of research and development, focusing on oncology, cardiovascular system, alimentary tract and metabolism, and central nervous system. The company was founded in 1994 and now has approximately 4,000 employees, including more than 300 R&D colleagues. Luye Pharma is committed to continued growth through innovation and internationalization, and currently has seven product candidates in late phase development for global markets, including one pending US NDA application, four on-going clinical trials in the US and two near EU NDA filing.
 

 

Akeagen LLC discovers and develops potent and highly differentiated human antibody therapeutics to improve the lives of patients with serious diseases. We focus our R&D on immune-oncology and autoimmune indications, an area with highly unmet needs. Our unique approach and portfolio are based on our leading proprietary Akeagen mouse platform technologies to effectively generate innovative bi-specific antibodies with superior properties for drug development. Akeagen LLC is entering into strategic collaborations with leading global pharmaceutical companies and institutions and has multiple promising product candidates in early and late preclinical developments.
 

Bioinformatics Solutions Inc (BSI) is well known for its PEAKS software suite and service platform for proteomics discovery and therapeutic protein characterization by LC-MS. The benchmark de novo sequencing capabilities offer advanced solutions for proteomic and therapeutic protein discovery and validation, particular in comprehensive peptide mapping, quantification of modifications and sequence variants, and sequence-related impurities. The mission of BSI is to advance drug discovery through professional proteomics software and service, and by collaborating and partnering with pharmaceutical and biotech companies in protein characterization. In the past decades, BSI has been dedicating to providing solutions to computational biomedicine with machine learning and advanced algorithms to gain comprehensive knowledge from proteomics, genomics, and medicine.
 

Livzon Mabpharm Inc., a clinical stage biotech company, was jointly founded by two publicly traded companies (Livzon Pharmaceuticals Group and JointCare). It focuses on the development, production and sales of biologics (both biosimilars and innovative drugs).  It is located in Zhuhai city, a beautiful coastal city rated as the most livable city in China. Our GMP facility is housed in a newly built 170,000 ft2 R&D center, and is designed to meet the FDA/EMA and CFDA cGMP standards. Currently, our development portfolio includes 13 molecules targeted towards indications in solid tumor, autoimmune diseases etc.  Six of Livzon’s molecules have already advanced to clinical trial both in China and US. We are positioned to become a leader in the biopharmaceutical industry in China and a key player in the global market.
 

 

 

 

Shanghai Henlius Biotech, Inc., (hereinafter referred to as “Henlius”), a joint venture between Fosun Pharma and a team of overseas scientists founded in December 2009, is primarily committed to research, development and industrialization of biosimilars, biobetters, and novel monoclonal antibodies using cutting-edge technology. The products currently developed by Henlius mainly cover the treatments of tumors and autoimmune diseases. With the strategy of globally-integrated Innovation, Henlius has established R&D laboratories in Shanghai, China; California, US; and Taipei. Headquartered in Shanghai Caohejing Hi-Tech Park, Henlius completed the construction of an internationally-advanced biopharmaceuticals pilot and industrial production facility at the end of 2015. As of now, Henlius has completed IND filing of 9 products with 16 indications, and started phase III clinical trials for 3 products. In October 2017, Henlius received a notice from the CFDA that its first new drug application (NDA), for the biosimilar rituximab HLX01, is officially under review, closing in on the first biosimilar approved in China. With the biosimilar as leading products, Henlius has been devoting continuous efforts in developing novel mAbs in a timely fashion. Three innovative products – HLX06, HLX07 and HLX10, developed by Henlius, have already obtained IND approvals by FDA, and are currently in Phase I clinical trials in Taiwan.

 

Hengrui Medicine is a research based company with head quarter in China. The company has research centers in major innovation harbors including Shanghai, Princeton (NJ), Australia, and in near future, Boston, MA. If you have interest ideas seeking collaboration or simply want to contact Hengrui, please email weimin.tang@hengruitherapeutics.com.
 

 

Focus on innovative biological and biosimilar drugs, addressing unmet medical needs in oncology, adjuvant chemotherapy, high cholesterol, autoimmune diseases etc. Advanced technology platforms of mAb, Antibody Drug Conjugate (ADC) and Fusion Protein have been developed. Looking for the opportunities of collaboration and cooperation in the biological field.

 

 A science-led biopharmaceutical company with a mission: Improving patients’ lives by identifying and acquiring differentiated innovated medicines that help people to feel better, live longer.

 

Biosion is dedicated to the discovery and preclinical development of innovative biologicals for unmet medical needs. Based on its proprietary H³ antibody platform, Biosion is able to develop superior and unique drug candidates to diversified clinical applications such as monoclonal antibody, bispecific antibody, ADC, CAR-T and gene therapy.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fox Rothschild is an AmLaw 100 full-service law firm with over 800 lawyers in 21 offices.  We provide services in Intellectual Property, Corporate, Entertainment, Financial Restructuring and Bankruptcy, Labor and Employment, Litigation, Real Estate, Taxation, and Wealth Planning.

WuXi Biologics provides integrated end-to-end and open-access technology platforms to empower anyone to discover, develop, and manufacture biologics from concept to clinical and commercial manufacturing in a truly ONE stop.

Waters Corporation creates business advantages for laboratory-dependent organizations by delivering scientific innovation to enable customers to make significant advancements. Waters helps customers make profound discoveries, optimize laboratory operations, deliver product performance, and ensure regulatory compliance with a connected portfolio of separations and analytical science, laboratory informatics, mass spectrometry, as well as thermal analysis.

BIOCYTOGEN LLC was established in 2008, and provides the fastest gene targeting services of mouse, rat and cells using CRISPR/Cas9 and pure C57BL/6 ES cell platforms. We provide 100% guarantee.

Systimmune, Inc is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug conjugates (ADCs).

Biortus is an innovation driven CRO specializing in structure-guided drug discovery services in both small molecule and biologic. Led by oversea trained structural biologists, the 50-biologist team at Biortus has expertise in molecular biology, protein chemistry, structural biology, and in vitro pharmacology. Biortus is equipped with state-of-the-art instrument including multiple fermenters, 10 units of GE AKTA systems, an Agilent TOF-MS, a Rigaku FR-E+ X-ray diffractor, Biacore T200 and S200, and guaranteed access to several high-end cryo-EM instruments in China. Biortus offers services in research grade antibody production, epitope mapping by negative staining, antigen/antibody structure determination by crystallography or cryo-EM, affinity characterization by SPR. Over the years, Biortus has delivered many de novo crystal structures including PD-1 and other checkpoint antigen/antibody complexes.